Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Events

Events

Evaluate

Thumbnail
July 31, 2023

ASRS 2023 – Syfovre’s side-effect questions still loom large

Thumbnail
July 28, 2023

Go or no go? Biogen and Astellas head towards key Pdufas

Article image
Vantage logo
June 24, 2023

ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin

A quarter of patients fail to stomach survodutide.

Article image
Vantage logo
June 24, 2023

Easl 2023 – Biomarkers back a new Nash player

Boston’s Novartis cast-off looks highly promising versus better-known projects.

Article image
Vantage logo
June 23, 2023

Easl 2023 – GLP-1 combos take on a milder form of Nash

Similarly acting agents from Merck & Co and Altimmune aim to improve NAFLD, with mixed results.

Article image
Vantage logo
June 22, 2023

Easl 2023 – Madrigal denies pivotal endpoint change

The primary analysis of Maestro-Nash had always relied on Nafld activity score, with a controversial trial entry change just a “typo”, the company says.

Article image
Vantage logo
June 21, 2023

ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer

Weight loss with Lilly’s oral GLP-1 agonist orforglipron falls short of the previously revealed “mid-teens” benchmark.

Article image
Vantage logo
June 19, 2023

ERA 2023 – longer is stronger for Vera

Proteinuria data with Vera’s IgAN project atacicept have improved over time, with a surprise benefit on the hard eGFR endpoint.

Article image
Vantage logo
June 12, 2023

EAACI – Intellia pushes forward in crowded rare swelling disease

Article image
Vantage logo
June 12, 2023

EHA 2023 – Editas hopes to be better, although late

Article image
Vantage logo
June 09, 2023

EHA 2023 – Roche heads to regulators with its Soliris challenger

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up